Sugi Predict

Sugi Predict / Compounds / SCHEMBL1139983

SCHEMBL1139983

SCHEMBL1139983

Fc1cc(Cl)cc(F)c1CBr

nearest known ligand 0.35

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.35
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ HTR2B P41595 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ TAAR1 Q96RJ0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30474266 0.88 ALDH1A1 (0.36) TSHRALDH1A1HPGD
SCHEMBL27127807 0.86 ERN1 (0.31) —
SCHEMBL24095329 0.86 ALDH1A1 (0.31) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL25247894 0.84 SCN4A (0.30) —
SCHEMBL29340263 0.80 ERN1 (0.44) —
SCHEMBL189364 0.78 RAPGEF4 (0.33) ALDH1A1TAAR1
SCHEMBL31722228 0.76 TSHR (0.37) TSHRALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL601770 0.76 DGAT1 (0.31) TAAR1
SCHEMBL3082888 0.74 TSHR (0.35) TSHRALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL4573381 0.74 TSHR (0.35) TSHRALDH1A1CYP1A2CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097037-A1 FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT SHIONOGI & CO., LTD. (JP) 2026-04-09 — — US disclosed
EP-4638436-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-10-29 — — EP disclosed
EP-4592285-A1 FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT Shionogi & Co., Ltd. (JP) 2025-07-30 — — EP disclosed
CN-119907794-A Fused ring compounds having GLP-1 receptor agonist action 盐野义制药株式会社 2025-04-29 — — CN disclosed
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) 2025-04-03 — — US disclosed
CN-119343339-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 — — CN disclosed
EP-4469444-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-04 — — EP disclosed
US-20240254118-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-08-01 — — US disclosed
CN-115215823-B FXR modulator, preparation method, pharmaceutical composition and application thereof 北京百思致道管理顾问中心(有限合伙) 2024-07-26 — — CN disclosed
US-20240239775-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF BEIJING BEST PATHWAY MANAGEMENT CONSULTING CENTER (LIMITED PARTNERSHIP) (CN) 2024-07-18 — — US disclosed
US-7648998-B2 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2010-01-19 — — US disclosed
US-7648998-B2 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2010-01-19 — — US disclosed
US-20090208456-A1 Imidazo[4,5-d]pyrimidines, their uses and methods of preparation GILEAD SCIENCES, INC. (US) 2009-08-20 — — US disclosed
US-20090208456-A1 Imidazo[4,5-d]pyrimidines, their uses and methods of preparation GILEAD SCIENCES, INC. (US) 2009-08-20 — — US disclosed
WO-2009074487-A1 INHIBITORS OF STEAROYL-COA DESATURASE F. HOFFMANN-LA ROCHE AG (CH) 2009-06-18 — — WO disclosed
US-20090149466-A1 INHIBITORS OF STEAROYL-COA DESATURASE GILLESPIE PAUL 2009-06-11 — — US disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 — — EP disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 — — WO disclosed
US-20070244148-A1 Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2007-10-18 — — US disclosed
US-20070244148-A1 Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2007-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149466-A1 INHIBITORS OF STEAROYL-COA DESATURASE SCD, SCD5, FADS2 TSHR 3235/4885HTR2A 3651/4885HTR2C 3399/4885
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR TSHR 140/4885HTR2A 134/4885HTR2C 152/4885
US-20070244148-A1 Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment ZC3HAV1, TPMT, DPP4 TSHR 3704/4885HTR2A 4380/4885HTR2C 2270/4885
US-20260097037-A1 FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, CCKAR, GCGR TSHR 47/4885HTR2A 403/4885HTR2C 269/4885
US-20240239775-A1 FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF SLC10A1, NR1H4, FXR1 TSHR 1009/4885HTR2A 4034/4885HTR2C 3853/4885
US-20240254118-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 TSHR 3833/4885HTR2A 4325/4885HTR2C 4527/4885
US-20090208456-A1 Imidazo[4,5-d]pyrimidines, their uses and methods of preparation TYMP, DPYD, TYMS TSHR 3634/4885HTR2A 3310/4885HTR2C 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.